RELMADA THERAPEUTICS, INC. Retained Earnings
RELMADA THERAPEUTICS, INC. (RLMD) had Retained Earnings of -$730.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$730.23M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$717.32M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$698.27M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$678.40M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$730.23M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$717.32M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$698.27M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$678.40M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$668.31M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$658.44M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$640.88M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$622.22M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$600.50M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$582.73M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$560.90M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$535.74M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$513.74M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$488.43M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$462.11M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$424.17M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$384.75M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$344.81M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$305.07M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$270.69M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$228.08M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$201.53M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$179.32M 10-K · filed 2022-03-25 |
| 2020-09-30 | -$158.55M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$141.65M 10-Q · filed 2020-08-12 |
| 2020-03-31 | -$130.53M 10-Q · filed 2020-05-15 |
| 2019-12-31 | -$119.86M 10-K · filed 2021-03-24 |
| 2019-09-30 | -$115.33M 10-Q · filed 2019-11-13 |
| 2019-06-30 | -$111.66M 10-K · filed 2021-03-24 |
| 2019-03-31 | -$107.54M 10-Q · filed 2019-05-15 |
| 2018-12-31 | -$104.85M 10-Q · filed 2019-02-13 |
| 2018-09-30 | -$97.72M 10-Q · filed 2018-11-13 |
| 2018-06-30 | -$94.34M 10-KT · filed 2020-03-26 |
| 2018-03-31 | -$90.99M 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$87.79M 10-Q · filed 2018-02-12 |
| 2017-09-30 | -$86.37M 10-Q · filed 2017-11-14 |
| 2017-06-30 | -$85.38M 10-K · filed 2018-09-28 |
| 2017-03-31 | -$83.75M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$81.77M 10-Q · filed 2017-02-10 |
| 2016-09-30 | -$80.74M 10-Q · filed 2016-11-10 |
| 2016-06-30 | -$79.10M 10-K · filed 2017-09-28 |
| 2016-03-31 | -$75.78M 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$73.92M 10-Q · filed 2016-02-05 |
| 2015-09-30 | -$71.46M 10-Q · filed 2015-11-06 |
| 2015-06-30 | -$76.12M 10-K · filed 2016-09-09 |
| 2015-03-31 | -$82.16M 10-Q · filed 2015-05-15 |
| 2014-12-31 | -$79.70M 10-Q · filed 2015-02-13 |
| 2014-06-30 | -$55.32M 10-K · filed 2015-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |